Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

ESCC · Total Neoadjuvant Treatment · Pathological Complete Response

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Taiwan University Hospital, Taipei, Taiwan
Contact: Study coordinator (Chien Huai Chuang, MD) · A00723@ntucc.gov.tw · +886911930410
Study coordinator · A00723@ntucc.gov.tw · +886911930410

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC) · Locally Advanced Unresectable Esophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Kaohsiung City, Taiwan · Kaohsiung City, Taiwan

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

ESCC · Advanced Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Annecy, France · Amiens, France